MOONLAKE IMMUNOTHERAPEUTICS (MLTX)

KY61559X1045 - Common Stock

56.66  +1.12 (+2.02%)

After market: 56.66 0 (0%)

MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ:MLTX (9/28/2023, 7:01:04 PM)

After market: 56.66 0 (0%)

56.66

+1.12 (+2.02%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)N/A N/A
Ins Owners3.77%
Inst Owners103.4%
Market Cap3.03B
Shares53.49M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts85.56
IPO10-20 2020-10-20
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

MLTX Daily chart

Company Profile

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 20 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Company Info

MOONLAKE IMMUNOTHERAPEUTICS

Dorfstrasse 29

Zug ZUG

P: 41415108022.0

Employees: 20

MLTX News

News Imagea day ago - InvestorPlace7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

News Image11 days ago - Investor's Business DailyThese 8 Stocks Are Outperforming Nvidia In 2023

Carvana has surged 1,001%, leading huge winners this year.

News Image11 days ago - Seeking AlphaAcelyrin, MoonLake rivalry heats up as both chase blockbuster PsA market

The rivalry between Acelyrin (SLRN) and MoonLake (MLTX) is heating up, with both companies slated to report key data on their drugs for psoriatic arthritis, or PsA. Read more here.

News Image16 days ago - The Motley FoolWhy Shares of MoonLake Immunotherapeutics Are Rising Tuesday

A competitor's clinical trial stumble may be benefiting MoonLake.

News Image17 days ago - Investor's Business DailyThe Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%

The companies are both working on treatments for a rare skin disease.

News Image17 days ago - Seeking AlphaAcelyrin tanks, rival MoonLake rallies on failed clinical trial (SLRN)

Acelyrin (SLRN) stock tanked in after-hours trading Monday after the company said its lead drug izokibep failed a mid-stage clinical trial, stoking shares of rival MoonLake (MLTX).

MLTX Twits

Here you can normally see the latest stock twits on MLTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example